Outcomes of surgical treatment for synchronous and metachronous lung cancer

Volume: 48 Number: 2 June 1, 2009
  • Turhan K
  • Yoldaş B
  • Çağırıcı U
  • Çakan A
EN TR

Outcomes of surgical treatment for synchronous and metachronous lung cancer

Abstract

Aim: At the present day, there is enough knowledge about the effectiveness and patient selection criterias of the surgical therapy for lung cancer. However, there are different opinions and inadequate data about the type of treatment and surgical results of synchronous tumors; defined as two primary tumors with different cell types at the same time and metachronous tumors; which is the second primary tumor that had been seen two years after curative surgical treatment of the first primary tumor. Material and Methods: In this report we reviewed the surgical results of 4 patients with primary lung cancer between January 1997-December 2006, retrospectively. 2 of these patients had synchronous and the other 2 had metachronous lung cancer. Results: All of the patients were male and had a mean age of 60 ± 8.1 (48-65) years. We performed 3 lobectomies and one wedge resection. Mean follow up time was 28.2 ± 15.1 (12-43) months. There was no recurrence during follow up period. Conclusion: Results of survival and disease free survival for synchronous and metachronous lung cancer gained by surgical treatment in our series were satisfactory and this result was consistent to the literature. However, for a certain determination further investigations are required.

Keywords

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

Turhan K

Yoldaş B

Çağırıcı U

Çakan A

Publication Date

June 1, 2009

Submission Date

June 1, 2009

Acceptance Date

-

Published in Issue

Year 1970 Volume: 48 Number: 2

Vancouver
1.Turhan K, Yoldaş B, Çağırıcı U, Çakan A. Senkron ve metakron akciğer kanserlerinde cerrahi tedavi sonuçları. EJM [Internet]. 2009 Jun. 1;48(2):85-8. Available from: https://izlik.org/JA34FD93RN

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.